No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
REGN250117C740000
- 1.30
- -6.20-82.67%
15min DelayClose Jan 14 16:00 ET
3.00High1.30Low
2.98Open7.50Pre Close9 Volume134 Open Interest740.00Strike Price2.52KTurnover52.81%IV7.30%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry1.30Extrinsic Value100Contract SizeAmericanOptions Type0.0789Delta0.0045Gamma600.76Leverage Ratio-0.7216Theta0.0043Rho47.38Eff Leverage0.0915Vega
Intraday
- 5D
- Daily
News
Regeneron Pharmaceuticals Shares Are Trading Lower After Citigroup Cut Its Price Target on the Stock From $895 to $795.
Could The Market Be Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Its Attractive Financial Prospects?
Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,185
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $950
Regeneron Pharma Is Maintained at Neutral by Citigroup
Regeneron Pharmaceuticals Analyst Ratings